ArticleScientific reports2025
Transcriptomic insights into GSDME-driven pyroptosis in head and neck cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study investigates the expression of pyroptosis-related genes (PRGs) in head and neck squamous cell carcinoma (HNSCC) and their potential role in the tumor immune microenvironment. Additionally, we conducted an in-depth transcriptomic analysis of HNSCC with high GSDME expression. This study utilized the curated TCGA-HNSCC and GSE65858 datasets to analyze differentially expressed genes (DEGs) associated with pyroptosis in HNSCC. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses were performed on these DEGs. The infiltration of 22 immune cell types was assessed using the CIBERSORTx algorithm. GSDME-overexpressing cells were sequenced using the Illumina NovaSeq 6000 platform, and immunohistochemistry (IHC) was conducted for validation. A total of 501 TCGA-HNSCC patient data and 270 tumor samples from the GSE65858 dataset were collected. Seventeen pyroptosis-related genes were found to have mutations in HNSCC samples, with TP53, CASP8, and NLRP3 exhibiting the highest mutation frequencies. GO enrichment analysis revealed that the DEGs were enriched in cellular components such as myofibrils and collagen-containing extracellular matrix, as well as in molecular functions including actin binding and receptor ligand activity. KEGG pathway enrichment analysis showed that DEGs were enriched in the focal adhesion biological pathway. GSEA analysis indicated a negative correlation between DEGs and the cytochrome P450 pathway. Transcriptomic analysis of high GSDME expression revealed a significant decrease in CK13 (KRT13) and CK19 (KRT19) in the GSDME-overexpressing group. Downregulated genes were significantly enriched in cell adhesion molecules and the arachidonic acid pathway. Immunohistochemistry confirmed a statistically significant reduction in CK13 and CK19 protein expression in the high GSDME expression group. Transcriptomic analysis of GSDME overexpression showed significant upregulation or downregulation of transcription factor families, including E2F, ETS, HMG, MYB, BZIP, and C2H2. Specifically, ELF3 from the ETS transcription factor family and PBX1 from the Homeobox transcription factor family were downregulated. GSDME is potentially associated with the ETS transcription factor ELF3 and the Homeobox transcription factor PBX1. The reduced expression of CK13 and CK19 in the GSDME-overexpressing group may serve as a potential mechanism by which GSDME inhibits HNSCC growth.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.